Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesEarnAISquareMore
Western Digital Q4 FY26 non-GAAP EPS more than doubles to $3.56 year-over-year; revenue rises 44% to $3.75 billion year-over-year

Western Digital Q4 FY26 non-GAAP EPS more than doubles to $3.56 year-over-year; revenue rises 44% to $3.75 billion year-over-year

ReutersReuters2026/08/05 20:14
  • Western Digital posted Q4FY26 non-GAAP revenue of USD 3.75 billion, up 44% year over year, with non-GAAP diluted EPS of USD 3.56, more than doubled.
  • Non-GAAP gross margin widened to 54.4%, up 13.1 percentage points year over year, while non-GAAP operating margin rose to 44.2%, up 16.1 points.
  • Free cash flow climbed to USD 1.28 billion, up 90% year over year, as cash flow from operations increased to USD 1.39 billion, up 86%.
  • Western Digital said it started shipping next-generation ePMR, with capacity of up to 40TB per drive.
  • For Q1FY27, it forecast non-GAAP revenue of USD 4.1 billion plus or minus USD 100 million, with non-GAAP diluted EPS of USD 4 plus or minus USD 0.15.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Western Digital Corporation published the original content used to generate this news brief on August 05, 2026, and is solely responsible for the information contained therein.

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

With support from Ober and Bain Capital, RNA rising star Adarx submits US IPO application

Adarx Pharmaceuticals Inc. has filed for an IPO in the United States to help fund the development of a pipeline of drugs aimed at treating various diseases by regulating gene expression.

智通财经2026/09/05 01:16
With support from Ober and Bain Capital, RNA rising star Adarx submits US IPO application